» Our new product pipeline significantly advances personalized medicine by applying next generation technologies to non-invasive cancer testing and digital health.
Non-Invasive Cancer Testing
Admera Health is developing multiple non-invasive cancer tests to reduce the need for biopsy collection and other invasive sample collection from patients. Non-invasive cancer tests are designed for early disease detection, treatment guidance, treatment response monitoring, and disease recurrence monitoring.
Our targeted enrichment system detects tumor DNA from blood or urine with exceptionally high sensitivity and specificity, eliminating time-consuming steps seen with most liquid biopsy analytic methods, enabling rapid turn-around of clinically actionable results to treating physicians.
Admera Health is developing its groundbreaking “Actionable Genomic Interpretation System” or AGIS™. It is a scalable and automatic system designed to provide end-to-end data analysis and interpretation solutions from raw sequencing data to clinically actionable reports. The interpretation system modules include personalized and actionable recommendations in the areas of pharmacogenomics, disease risk, inherited disease and nutrigenomics. The health management system focuses on smart phone apps to provide patients and consumers with relevant genomic data. Integrating these components together, AGIS™ is able to provide a comprehensive digital health solution for both physicians and patients.